{"id":905530,"date":"2025-11-04T18:41:11","date_gmt":"2025-11-04T23:41:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/"},"modified":"2025-11-04T18:41:11","modified_gmt":"2025-11-04T23:41:11","slug":"viking-therapeutics-to-participate-at-upcoming-investor-conferences-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/","title":{"rendered":"Viking Therapeutics to Participate at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 4, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at two upcoming investor conferences.\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" title=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" alt=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Details of the company&#8217;s participation are as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Stifel 2025 Healthcare Conference <br \/><\/b>Details: Viking management will participate in a fireside chat and in investor meetings <br \/>Conference Dates: <span class=\"xn-chron\">November 11-13, 2025<\/span><br \/>Fireside Chat Time\/Date: 4:40 \u2013 <span class=\"xn-chron\">5:10 p.m. Eastern Time on Tuesday<\/span>, November 11, 2025 <br \/>Location: <span class=\"xn-location\">New York, NY<\/span><\/p>\n<\/li>\n<li>\n          <b>Jefferies 2025 Global Healthcare Conference \u2013 <span class=\"xn-location\">London<\/span><br \/><\/b>Details: Viking management will deliver a corporate presentation and participate in investor meetings <br \/>Conference Dates: <span class=\"xn-chron\">November 17-20, 2025<\/span><br \/>Presentation Time\/Date: 8:00 \u2013 <span class=\"xn-chron\">8:25 a.m.<\/span> Greenwich Mean Time (3:00 \u2013 <span class=\"xn-chron\">3:25 a.m. Eastern Time<\/span>) on <span class=\"xn-chron\">Wednesday, November 19, 2025<\/span>, webcast available <br \/>Location: <span class=\"xn-location\">London, UK<\/span><\/li>\n<\/ul>\n<p>A live webcast of the Jefferies presentation may be accessed via a link on the Viking Therapeutics website in the Investors &amp; Media section under\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547643-1&amp;h=2651818594&amp;u=http%3A%2F%2Fir.vikingtherapeutics.com%2Fwebcasts&amp;a=Webcasts\" target=\"_blank\" rel=\"nofollow\">Webcasts<\/a>.\u00a0 Additionally, a replay of the webcast will be available on the Viking website following the conferences.\u00a0<\/p>\n<p>\n        <b>About Viking Therapeutics, Inc. <\/b>\n      <\/p>\n<p>Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.\u00a0 Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients&#8217; lives.\u00a0 Viking&#8217;s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (<span>GLP-1<\/span>) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. \u00a0The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). \u00a0Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. \u00a0Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. \u00a0Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. \u00a0The compound successfully achieved both the primary and secondary endpoints in a Phase\u00a02b\u00a0study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.\u00a0 In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.\u00a0 The company&#8217;s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. \u00a0In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).\u00a0 In a Phase\u00a01b\u00a0clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.<\/p>\n<p>For more information about Viking Therapeutics, please visit\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4547643-1&amp;h=4160481074&amp;u=https%3A%2F%2Fwww.vikingtherapeutics.com%2F&amp;a=www.vikingtherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.vikingtherapeutics.com<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA13492&amp;sd=2025-11-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302602732.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302602732.html<\/a><\/p>\n<p>SOURCE  Viking Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA13492&amp;Transmission_Id=202511041605PR_NEWS_USPR_____LA13492&amp;DateId=20251104\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212; Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at two upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Stifel 2025 Healthcare Conference Details: Viking management will participate in a fireside chat and in investor meetings Conference Dates: November 11-13, 2025Fireside Chat Time\/Date: 4:40 \u2013 5:10 p.m. Eastern Time on Tuesday, November 11, 2025 Location: New York, NY Jefferies 2025 Global Healthcare Conference \u2013 LondonDetails: Viking management will deliver a corporate presentation and participate in investor meetings Conference Dates: November 17-20, 2025Presentation Time\/Date: 8:00 \u2013 8:25 a.m. Greenwich &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viking Therapeutics to Participate at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905530","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212; Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at two upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Stifel 2025 Healthcare Conference Details: Viking management will participate in a fireside chat and in investor meetings Conference Dates: November 11-13, 2025Fireside Chat Time\/Date: 4:40 \u2013 5:10 p.m. Eastern Time on Tuesday, November 11, 2025 Location: New York, NY Jefferies 2025 Global Healthcare Conference \u2013 LondonDetails: Viking management will deliver a corporate presentation and participate in investor meetings Conference Dates: November 17-20, 2025Presentation Time\/Date: 8:00 \u2013 8:25 a.m. Greenwich &hellip; Continue reading &quot;Viking Therapeutics to Participate at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T23:41:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\",\"datePublished\":\"2025-11-04T23:41:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/\"},\"wordCount\":533,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/\",\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"datePublished\":\"2025-11-04T23:41:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212; Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate at two upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: Stifel 2025 Healthcare Conference Details: Viking management will participate in a fireside chat and in investor meetings Conference Dates: November 11-13, 2025Fireside Chat Time\/Date: 4:40 \u2013 5:10 p.m. Eastern Time on Tuesday, November 11, 2025 Location: New York, NY Jefferies 2025 Global Healthcare Conference \u2013 LondonDetails: Viking management will deliver a corporate presentation and participate in investor meetings Conference Dates: November 17-20, 2025Presentation Time\/Date: 8:00 \u2013 8:25 a.m. Greenwich &hellip; Continue reading \"Viking Therapeutics to Participate at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T23:41:11+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viking Therapeutics to Participate at Upcoming Investor Conferences","datePublished":"2025-11-04T23:41:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/"},"wordCount":533,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/","name":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","datePublished":"2025-11-04T23:41:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics to Participate at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905530"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905530\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}